Evidence map›Paper›PMID 31368839›Full record

ArticleNucleic acid therapeutics2019

Hybrid Mouse Diversity Panel Identifies Genetic Architecture Associated with the Acute Antisense Oligonucleotide-Mediated Inflammatory Response to a 2'-

Elaine Pirie, Patrick Cauntay, Wuxia Fu, Shayoni Ray, Calvin Pan, Aldonis J Lusis, Jill Hsiao, Sebastien A Burel, Padma Narayanan, Rosanne M Crooke and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nucleic acid therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Elaine PirieCardiovascular Antisense Drug Discovery Group, Ionis Pharmaceuticals, Carlsbad, California.
Patrick CauntayPreclinical Development, Ionis Pharmaceuticals, Carlsbad, California.
Wuxia FuCardiovascular Antisense Drug Discovery Group, Ionis Pharmaceuticals, Carlsbad, California.
Shayoni RayCardiovascular Antisense Drug Discovery Group, Ionis Pharmaceuticals, Carlsbad, California.
Calvin PanDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, California.
Aldonis J LusisDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, California.
Jill HsiaoPreclinical Development, Ionis Pharmaceuticals, Carlsbad, California.
Sebastien A BurelPreclinical Development, Ionis Pharmaceuticals, Carlsbad, California.
Padma NarayananPreclinical Development, Ionis Pharmaceuticals, Carlsbad, California.
Rosanne M CrookeCardiovascular Antisense Drug Discovery Group, Ionis Pharmaceuticals, Carlsbad, California.
Richard G LeeCardiovascular Antisense Drug Discovery Group, Ionis Pharmaceuticals, Carlsbad, California.
Ionis Pharmaceuticals (United States) · USUniversity of California, Los Angeles · US

Funding

ULTRASTRUCTURE OF THE INTIMA IN EARLY LESION FORMATIONP01HL030568 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TONTONOZ, PETER J · 1985 to 2019
$55.2M
Systems genomics of metabolic syndrome traitsP01HL028481 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DAVIS, RICHARD C · 1985 to 2019
$50.2M
Systems Approach to Unraveling the Genetic Basis of Heart FailureR01HL114437 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DENG, MARIO C., KARMA, ALAIN S · 2013 to 2016
$4.7M
A Systems Approach to Dissect Genetic Basis of Heart FailureR01HL123295 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LUSIS, ALDONS JAKE, WANG, YIBIN · 2014 to 2017
$2.6M
NHLBI NIH HHS P01 HL028481NHLBI NIH HHS P01 HL030568NHLBI NIH HHS R01 HL114437NHLBI NIH HHS R01 HL123295
6 · The paper itself

Abstract

Although antisense oligonucleotides (ASOs) are well tolerated preclinically and in the clinic, some sequences of ASOs can trigger an inflammatory response leading to B cell and macrophage activation in rodents. This prompted our investigation into the contribution of genetic architecture to the ASO-mediated inflammatory response. Genome-wide association (GWA) and transcriptomic analysis in a hybrid mouse diversity panel (HMDP) were used to identify and validate novel genes involved in the acute and delayed inflammatory response to a single 75 mg/kg dose of an inflammatory 2'-

Indexed as

Genetic Predisposition to DiseaseAnimalsCCAAT-Enhancer-Binding Protein-betaCell LineChemokine CCL2Chemokine CCL4Gene Expression ProfilingGenome-Wide Association StudyHumansInflammationMiceOligonucleotides, AntisensePolymorphism, Single NucleotideProtein Serine-Threonine KinasesTranscriptomeCCAAT-Enhancer-Binding Protein-betaCcl2 protein, mouseCcl4 protein, mouseCebpb protein, mouseChemokine CCL2Chemokine CCL4Oligonucleotides, AntisenseProtein Serine-Threonine KinasesSik1 protein, mouseeQTLGWASinflammationoligonucleotide

Identifiers

PMID31368839
PMCPMC6765210
OpenAlexW2966402717

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.